TITLE

Oral cancer treatment costs in Greece and the effect of advanced disease

AUTHOR(S)
Zavras, Athanasios; Andreopoulos, Nikos; Katsikeris, Nikos; Zavras, Dimitrios; Cartsos, Vassiliki; Vamvakidis, Athanasios
PUB. DATE
January 2002
SOURCE
BMC Public Health;2002, Vol. 2, p12
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The main purpose of the study was to quantify the direct costs of oral cancer treatment to the healthcare system of Greece. Another aim was to identify factors that affect costs and potential cost reduction items. More specifically, we examined the relationship between stage of disease, modality of treatment and total direct costs. Methods: The medical records and clinic files of the Oral and Maxillofacial Clinic of the Athens General Hospital "Genimatas" were abstracted to investigate clinical treatment characteristics, including length of hospitalization, modes of treatment, stage of disease etc. Records of 95 patients with oral squamous cell carcinoma (OSSC), with at least six months of follow-up, were examined. The clinical data was then used to calculate actual direct costs, based on 2001 market values. Results: The mean total direct costs for OSSC treatment estimated at euro 8,450 or approximately US$ 7,450. Costs depended on the stage of the disease, with significant increases in stages III and IV, as compared with stages I and II (p < 0.05). Multi-modality treatment applied mainly to patients in stages III and IV was the factor that affected the cost. Disease stage was also associated with the total duration of hospitalization (p < 0.05). Conclusions: The clinical management of advanced oral cancer is strongly associated with higher costs. Although the ideal would be to prevent cancer, the combination of high-risk screening, early diagnosis and early treatment seems the most efficient way to reduce costs, and most importantly, prolong life.
ACCESSION #
29336469

 

Related Articles

  • Determinants of End-of-Life Expenditures in Patients with Oral Cancer in Taiwan: A Population-Based Study. Lee, Ching-Chih; Chang, Ting-Shou; Wu, Cheng-Jung; Yang, Ching-Chieh; Chen, Po-Chun // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Background: To investigate the association of basic demographic data, socioeconomic status, medical services, and hospital characteristics with end-of-life expenditure in patients with oral cancer in Taiwan who died between 2009 to 2011. Methods: This nationwide population-based, retrospective...

  • Cost-effectiveness of oral cancer screening: results from a cluster randomized controlled trial in India. Subramanian, Sujha; Sankaranarayanan, Rengaswamy; Bapat, Bela; Somanathan, Thara; Thomas, Gigi; Mathew, Babu; Vinoda, Jissa; Ramadas, Kunnambath // Bulletin of the World Health Organization;Mar2009, Vol. 87 Issue 3, p200 

    Objective To evaluate oral cancer screening by visual inspection. Methods A cluster randomized controlled trial was initiated in Trivandrum district, Kerala, India. Of 13 population clusters, seven were randomly allocated to three rounds of screening between 1996 and 2004, while standard care...

  • Association between Provider Volume and Healthcare Expenditures of Patients with Oral Cancer in Taiwan: A Population-Based Study. Chen, Li-Fu; Ho, Hsu-Chueh; Su, Yu-Chieh; Lee, Moon-Sing; Hung, Shih-Kai; Chou, Pesus; Lee, Ching-Chieh J.; Lin, Li-Chu; Lee, Ching-Chih // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Background: Oral cancer requires considerable utilization of healthcare services. Wide resection of the tumor and reconstruction with free flap are widely used. Due to high recurrence rate, close follow-up is mandatory. This study was conducted to explore the relationship between the healthcare...

  • SCREENING PRICES VARY WIDELY.  // Medical Economics;6/25/2012, Vol. 89 Issue 12, p14 

    The article informs that a research from the firm Healthcare Change has found that prices charged by healthcare providers for the most common screenings like diabetes, Pap smears, lipid panels and mammograms, vary widely.

  • Cash boost for cancer care. Hartley, Jo // GP: General Practitioner;3/25/2002, p13 

    Reports on the government allocation for primary care cancer programs in Great Britain. Availability of funds through Cancer Service Collaborative; Objective of the project; Standards of care outlined in the program.

  • Flatten the cost curve for cancer.  // PharmacoEconomics & Outcomes News;6/25/2011, Issue 631, p9 

    The article discusses projected annual direct costs for cancer care in the U.S. which are expected to increase from 104 billion U.S. dollars in 2006 to more than 170 billion U.S. dollars in 2010, as it suggests behavioral changes to decrease costs such as limiting chemotherapy based on patient's...

  • Cancer care costs could increase by 66% in 2020.  // Hem/Onc Today;1/25/2011, Vol. 12 Issue 2, p25 

    The article discusses a study which reported the projected increase in costs associated with cancer care in 2020.

  • Health care costs five times higher for patients who disenroll from hospice care. Shafer, Emily // Hem/Onc Today;10/25/2010, Vol. 11 Issue 20, p33 

    The article discusses research being done on the cost of medical care of terminal cancer patients after disenrollment, which references a study by Melissa Carlson and colleagues in the "Journal of Clinical Oncology."

  • IOM: US faces cancer care crisis.  // Hem/Onc Today;10/10/2013, Vol. 14 Issue 19, p6 

    The article reports that the U.S. is nearing a crisis-point in cancer care delivery because of increased demand, rapidly rising costs, reductions in the oncology workforce, and the increasing complexity of the disease and targeted treatments, according to a report by the Institute of Medicine.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics